Shoppers of biotech news are watching Mana.bio as it adds heavyweight industry talent and prepares to unveil machine-learning-designed lipid nanoparticles at ASGCT 2026, a development that could make in vivo T‑cell engineering cheaper, faster and more accessible.

Essential Takeaways

  • New leadership: Mana.bio has added Thaminda Ramanayake to its board, Michelle Lynn‑Hall as a board observer and Guy Van Meter as strategic advisor, bringing deep mRNA, LNP and BD experience.
  • ASGCT presentation: The company will present Abstract 1083 on 12 May 2026, showing ML-driven LNPs for in vivo T‑cell transfection with NHP and mouse efficacy data.
  • Proof in animals: Lead candidates reportedly delivered payloads to T cells in non‑human primates after a single dose and cleared B‑cell tumours in mice after repeated dosing.
  • AI platform edge: Mana.bio’s models are trained on a very large curated LNP dataset and include a predictive safety model to de‑risk early LNP design.
  • Practical upside: If validated, these LNPs could simplify CAR‑T style therapies by avoiding complex ex‑vivo manufacturing, potentially lowering cost and expanding access.

Why the new hires matter: business sense meets bench expertise

Mana.bio’s fresh appointments read like a who’s who of commercial and scientific dealmaking, and that matters because scale in genetic medicine isn’t just about a lab win, it’s about partnerships and routes to market. Thaminda Ramanayake brings two decades of BD chops from CureVac, Sanofi and others, while Michelle Lynn‑Hall contributes deep LNP and genetic medicines experience from Moderna and Eli Lilly. Guy Van Meter adds decades of antibody-platform commercialisation experience. Together they give the company a more complete toolkit for turning promising formulations into partnered programmes or clinical candidates, which is the hard part of biotech.

What the ASGCT abstract promises , and what to watch for

Mana.bio’s poster at ASGCT, “Machine Learning‑Driven Design of Lipid Nanoparticles for In Vivo T‑Cell Engineering,” will showcase how their ML suite predicted transfection, CAR function, safety and stability. The most eye‑catching claims are single‑dose T‑cell delivery in non‑human primates and near‑complete tumour clearance in mouse models. Those are encouraging sensory details , the NHP delivery was measured with a fluorescent reporter, so it’s visually demonstrable data , but the field will want full methods, controls and reproducibility before getting excited about clinical impact.

How AI and the LNP dataset change the design game

Mana.bio says its models were trained on the world’s largest curated LNP dataset, and that’s the sort of scale you need to spot non‑obvious structure–function relationships. Combining machine learning with a predictive safety model helps prioritise candidates that balance tropism and tolerability, which is a persistent bottleneck for extrahepatic RNA delivery. For researchers and industry watchers, the takeaway is that AI can dramatically shorten the iterative chemistry‑biology cycle , but model transparency and independent validation will be critical next steps.

Why in vivo T‑cell engineering could be a game changer

Current CAR‑T therapies depend on bespoke ex‑vivo manufacturing: you extract a patient’s cells, modify them and re‑infuse them. That’s effective but expensive and logistically hard to scale. If passive‑targeted LNPs can reliably transfect T cells in the body with therapeutic CAR constructs, you replace a weeks‑long, centralised process with a simpler dosing regimen. That could broaden access beyond specialised centres and reduce costs, though safety, off‑target effects and durability of response remain the big questions.

What clinicians, investors and patients should look for next

At ASGCT we’ll be looking for the poster’s experimental details: dosing, biodistribution, immunogenicity readouts, durability and reproducibility across cohorts. Investors will want a clear path to IND‑enabling studies and partnership terms; clinicians will want safety data that addresses cytokine release and long‑term effects; patients and advocates will want clarity on timelines. If Mana.bio’s platform truly delivers tissue‑specific, safe RNA delivery guided by AI, it’s a small but fundamental shift in how genetic medicines are developed.

It's a small change that could make every T‑cell therapy simpler and more accessible.

Source Reference Map

Story idea inspired by: [1]

Sources by paragraph: